• Tuomas Natukka, Joonas Haapasalo, Tomi Kivioja, Linnea Rajala, Jani Raitanen, Jaakko Nevalainen, Sirpa-Liisa Lahtela, Kristiina Nordfors, Minna Rauhala, Arja Jukkola, Juhana Frösen, Pauli Helén, Anssi Auvinen, and Hannu Haapasalo.
• Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland. Electronic address: tuomas.natukka@tuni.fi.
• World Neurosurg. 2023 Jul 7.

BackgroundThe purpose of our study was to analyze the impact of time interval from referral to surgery and from surgery to adjuvant treatment on survival of adult isocitrate dehydrogenase-wild-type (IDH-wt) glioblastomas.MethodsData on 392 IDH-wt glioblastomas diagnosed at the Tampere University Hospital in 2004-2016 were obtained from the electronic patient record system. Piecewise Cox regression was used to calculate hazard ratios for different time intervals between referral and surgery, as well as between surgery and adjuvant treatments.ResultsThe median survival time from primary surgery was 9.5 months (interquartile range: 3.8-16.0). Survival among patients with an interval exceeding 4 weeks from referral to surgery was no worse compared to <2 weeks (hazard ratio: 0.78, 95% confidence interval: 0.54-1.14). We found indications of poorer outcome when the interval from surgery to radiotherapy exceeded 30 days (hazard ratio: 1.42, 95% confidence interval: 0.91-2.21 for 31-44 days; and 1.59, 0.94-2.67 for over 45 days).ConclusionsInterval from referral to surgery in the range of 4-10 weeks was not associated with decreased survivals in IDH-wt glioblastomas. In contrast, delay exceeding 30 days from surgery to adjuvant treatment may decrease long-term survival.Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

5 keywords...

hide…